Allied Market Research recently published a report, titled, Syphilis Testing Market by By Type (Primary & Secondary Syphilis, Others), by Location of Testing (Laboratory testing, Point of care (POC) testing): Global Opportunity Analysis and Industry Forecast, 2020-2030.” According to the report, the global syphilis testing industry was pegged at $1.1 billion in 2020, and is expected to reach $1.9 billion by 2030, growing at a CAGR of 5.6% from 2021 to 2030.

Get Free Sample PDF of Syphilis Testing Market:

https://www.alliedmarketresearch.com/request-sample/675

COVID-19 Scenario –

  • The outbreak of the Covid-19 pandemic negatively impacted the global syphilis testing market. This is owing to decrease in the number of patient visits to hospitals and clinics for testing, as a result of the suspension of various elective procedures and outpatient visits, which reduced the demand for syphilis tests.
  • Between March 2019 and May 2020, the Syphilis testing rate fell by 64%.

Syphilis is a sexually transmitted disease caused by Treponema pallidum bacteria. Syphilis tests are used for screening and detection of antibodies against bacteria into the patients’ blood. There are various complications related to syphilis infection, such as infertility in both, men and women, ectopic pregnancy, cervical cancer in women and congenital mortality, and infections. Treponemal tests applied for the screening of bacterial infection includes the Treponema pallidum particle agglutination (TP-PA) and fluorescent treponemal antibody (FTA-ABS). Non-treponemal tests are relatively simple to perform and interpret, give rapid results, and are economic. However, non-treponemal tests require laboratory equipment and trained personnel to perform and interpret test reactions. Non-treponemal tests include, Rapid Plasma Reagin (RPR), which is an improved version of the Venereal Disease Research Laboratory (VDRL) test and tests for the same antigen.

Ask more about Syphilis Testing Market:

https://www.alliedmarketresearch.com/request-for-customization/675

KEY FINDINGS OF STUDY

  • By type, the secondary syphilis testing segment was the highest contributor to the market in 2020.
  • By location of testing, the laboratory test segment was the highest contributor to the market in 2020.
  • Region-wise, North America is the  largest revenue share in 2020. However, Europe  is anticipated to grow at the highest CAGR during the forecast period.

The primary & secondary syphilis segment to dominate by 2030-

By type, the primary & secondary syphilis segment accounted for nearly two-thirds of the global syphilis testing market share in 2020, and is anticipated to retain its dominance throughout the forecast period. This is attributed to increase in syphilis infection rate, availability of screening test such as automated treponemal tests (TTs) that includes enzyme immune-assays (EIAs) under primary syphilis & RPR card, the serological test VDRL, and USR for secondary syphilis. Moreover, the same segment would showcase the fastest CAGR of 5.7% by 2030.

The laboratory testing segment held the lion’s share in 2020-

Based on location of testing, the laboratory testing segment held the lion’s share in 2020, contributing to more than four-fifths of the global syphilis testing market, and is expected to continue its lead during the forecast period. However, thepoint of care (POC) testing segment is expected to witness the highest CAGR of 6.8% by 2030, due to increase in prevalence of syphilis infection, the laboratory test is cost efficient, convenient and confidential for use in hospitals & clinics.

North America, to lead the trail in terms of revenue-

By region, North America, garnered the major share in 2020, contributing to more than one-third of the global syphilis testing market and is expected to dominate the market during the forecast period. However, LAMEA region is expected grow at the fastest CAGR of 6.2% by 2030.

Buy Now with Discount (Till 20th August 2022):

https://www.alliedmarketresearch.com/checkout-final/7769a30b37938d59fe71dbdf3c60313e

Leading market players-

  • Becton Dickinson And Company
  • Hologic, Inc.
  • Cepheid Inc.
  • DiaSorin
  • Abbott Laboratories
  • Bio-Rad Laboratories
  • Beckman Coulter Inc
  • F. Hoffmann-La Roche
  • Affymetrix, Inc
  • Siemens healthcare

About Us:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

Contact Us:

David Correa

Portland, OR, United States

USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022,

UK: +44-845-528-1300

Hong Kong: +852-301-84916

India (Pune): +91-20-66346060

Fax: +1(855)550-5975

help@alliedmarketresearch.com

Web: https://www.alliedmarketresearch.com

Leave a comment

Your email address will not be published.